Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-037982
Filing Date
2025-04-23
Accepted
2025-04-23 16:03:19
Documents
22
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm2427843-1_def14a.htm   iXBRL DEF 14A 1178167
5 GRAPHIC lg_kerostherapeutics-4c.jpg GRAPHIC 11473
6 GRAPHIC sg_jasbirseehra-4c.jpg GRAPHIC 8075
7 GRAPHIC sg_esthercho-bw.jpg GRAPHIC 5604
8 GRAPHIC bc_capvsnetloss-4c.jpg GRAPHIC 49025
9 GRAPHIC bc_capvstsr-4c.jpg GRAPHIC 62674
10 GRAPHIC px_24kerosproxy01pg01-bw.jpg GRAPHIC 308849
11 GRAPHIC px_24kerosproxy01pg02-bw.jpg GRAPHIC 414158
  Complete submission text file 0001104659-25-037982.txt   4182135

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kros-20241231.xsd EX-101.SCH 8846
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kros-20241231_lab.xml EX-101.LAB 36300
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kros-20241231_pre.xml EX-101.PRE 7743
25 EXTRACTED XBRL INSTANCE DOCUMENT tm2427843-1_def14a_htm.xml XML 143344
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39264 | Film No.: 25861358
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)